Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiMA study of lisdexamfetamine for methamphetamine dependence
ACTRN12617000657325Phase 3Completed
- Sponsor
- University of New South Wales
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in methamphetamine use disorder (MUD) and substance use disorder (SUD) comparing Lisdexamfetamine + CBT with Placebo + CBT (2 arms). Primary endpoints: Methamphetamine use reduction at Week 19 and Safety at Week 19. Started May 2018; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
methamphetamine use disorder (MUD)substance use disorder (SUD)
Beyond the preview
Go deeper on ACTRN12617000657325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000657325.